We are live on ! Find out more

489 hedge funds and large institutions have $8.03B invested in Sanofi in 2019 Q1 according to their latest regulatory filings, with 52 funds opening new positions, 142 increasing their positions, 197 reducing their positions, and 54 closing their positions.

New
Increased
Maintained
Reduced
Closed

273% more call options, than puts

Call options by funds: $61.3M | Put options by funds: $16.4M

3% more capital invested

Capital invested by funds: $7.77B → $8.03B (+$257M)

0.23% more ownership

Funds ownership: 14.29%14.52% (+0.23%)

4% less first-time investments, than exits

New positions opened: 52 | Existing positions closed: 54

2% less funds holding

Funds holding: 501489 (-12)

28% less repeat investments, than reductions

Existing positions increased: 142 | Existing positions reduced: 197

36% less funds holding in top 10

Funds holding in top 10: 149 (-5)

Holders
489
Holders Change
-12
Holders Change %
-2.4%
% of All Funds
10.55%
Holding in Top 10
9
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-35.71%
% of All Funds
0.19%
New
52
Increased
142
Reduced
197
Closed
54
Calls
$61.3M
Puts
$16.4M
Net Calls
+$44.9M
Net Calls Change
+$14.3M

SNY Hedge Fund Activity: Q1 2019 in Review

489 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Sanofi (SNY) for Q1 2019, worth a combined $8.03B — up 3.3% from $7.77B a quarter earlier.

Sellers outnumbered buyers: 54 funds closed out of SNY and 52 opened new positions — a net loss of 2 holders — while 197 trimmed existing stakes and 142 added.

The largest buyer was Lazard Asset Management, adding an estimated $102M. The largest seller was Hotchkis & Wiley Capital Management, cutting an estimated $70M.

  • 489 institutional investors held Sanofi (SNY) as of Q1 2019, down from 501 in Q4 2018.
  • Funds reported $8.03B of Sanofi stock for Q1 2019, up 3.3% quarter-over-quarter.
  • 52 funds opened new Sanofi positions in Q1 2019 and 54 closed out, a net change of -2 holders.
  • The largest Sanofi buyer in Q1 2019 was Lazard Asset Management, an estimated $102M added.
  • The largest Sanofi seller in Q1 2019 was Hotchkis & Wiley Capital Management, an estimated $70M sold.

Based on aggregated 13F filings for Q1 2019.